Skip to main content

Common Sickle Cell Drug, Hydroxyurea, Won't Harm Female Fertility

Medically reviewed by Carmen Pope, BPharm. Last updated on July 22, 2024.

By Ernie Mundell HealthDay Reporter

MONDAY, July 22, 2024 -- A drug called hydroxyurea has long been used to fight sickle cell disease, but some female patients may have shied away from it due to concerns that it could harm future fertility.

Those fears may be unfounded: A new study finds that hydroxyurea has no effect on what's known as "ovarian reserve" -- the number of healthy eggs a girl or woman may have on hand to conceive.

Based on the new findings, women with sickle cell disease "should be more confident in hydroxyurea as a therapy," said study lead author Dr. Tamara Diesch-Furlanetto, of the University Children’s Hospital Basel in Switzerland.

Hydroxyurea cuts down on sickle cell-related crises and hospitalizations "and, according to the data from this study, doesn’t impact fertility," she said in a news release from the American Society of Hematology (ASH).

According to ASH, over 100,000 people in the United States currently suffer from sickle cell disease, where a genetic aberration creates bent (sickle-shaped) blood cells that can get lodged in blood vessels.

Sometimes these blockages are so severe as to impede that flow of blood to organs, creating a sometimes fatal condition known as a vaso-occlusive crisis (VOC).

The disease disproportionately affects Black Americans. According to the U.S. Centers for Disease Control and Prevention, sickle cell affects one in every 365 Black American births and one out of every 16,300 Hispanic American births.

Hydroxyurea has been in use among sickle cell patients since the 1960s, and it's proven to reduce the frequency of VOCs and blood transfusions.

However, there have long been questions around the drug's impact on fertility. That's because girls and women who used the drug tended to have lower levels of a hormone linked to ovarian function and fertility.

To help settle the question, Diesch-Furlanetto and colleagues collected ovarian tissues harvested from 76 female patients (averaging about 10 years of age) with sickle cell disease who had opted to undergo cryopreservation ("egg freezing") prior to stem cell transplant therapy.

Thirty-five of the young patients had taken hydroxyurea prior to having their ovarian tissue harvested, while 50 others hadn't yet gone through puberty when the procedure took place.

One way to measure ovarian reserve in tissues is to examine the density of what are known as primordial follicles. These are present at birth and comprise the majority of the ovaries, the researchers explained.

They report no significant differences in primordial follicular density between the girls who had undergone hydroxyurea treatment and those who hadn't.

“This is the first time we can say, after examining histological tissue, that hydroxyurea doesn’t impact ovarian reserve,” Diesch-Furlanetto said in an ASH news release.

She added that the new data is in line with her personal experience caring for women with sickle cell disease: Many who've taken hydroxyurea have gone on to conceive and bear children.

Diesch-Furlanetto's advice: "Individuals living with sickle cell disease should still consider preserving ovarian tissue before [stem cell therapy], but it’s not obligatory if they are just being treated with hydroxyurea."

The findings might have financial implications for patients, well. That's because fears around hydroxyurea's impact on fertility have some female patients opting to freeze their eggs. But as the ASH news release noted, as of early 2023, only "11 states mandated private insurance coverage for fertility preservation, with public insurance covering it in just two states."

The new findings were published July 18 in the journal Blood Advances.

Sources

  • American Society of Hematology, news release, July 18, 2024

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Chemo Drug, Hydroxyurea, Effective For Kids With Sickle Cell Disease

MONDAY, April 21, 2025 -- An oral chemotherapy drug can safely and effectively manage sickle cell disease in children, a new study says. Children taking hydroxyurea had fewer ER...

Menstrual Cycle Could Be Contributing To Sickle Cell Pain Events

MONDAY, April 14, 2025 -- Women with sickle cell disease often have pain crises around the time of their period, and researchers now think they know why. Inflammation increases...

First Patient Cured of Sickle Cell Anemia

MONDAY, March 17, 2025 -- For 21 years, Sebastien Beauzile lived with the chronic pain of sickle cell anemia.  Now, thanks to a groundbreaking genetic treatment, he is the...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.